Miguel Muñoz Gomez
A5036060492- Ferrocene Chemistry and Applications
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Estrogen and related hormone effects
- Genomics and Chromatin Dynamics
- Cancer Cells and Metastasis
- Pancreatic function and diabetes
- Fibroblast Growth Factor Research
- Cancer-related gene regulation
- FOXO transcription factor regulation
- Neuroendocrine Tumor Research Advances
- Proteoglycans and glycosaminoglycans research
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Protein Tyrosine Phosphatases
- Cancer Genomics and Diagnostics
Dana-Farber Cancer Institute
2022-2024
Abstract KMT2C and KMT2D , encoding histone H3 lysine 4 methyltransferases, are among the most commonly mutated genes in triple-negative breast cancer (TNBC). However, how these mutations may shape epigenomic transcriptomic landscapes to promote tumorigenesis is largely unknown. Here we describe that deletion of Kmt2c or Kmt2d non-metastatic murine models TNBC drives metastasis, especially brain. Global chromatin profiling immunoprecipitation followed by sequencing revealed altered H3K4me1,...
Abstract Most invasive lobular breast cancers (ILC) are of the luminal A subtype and strongly hormone receptor–positive. Yet, ILC is relatively resistant to tamoxifen associated with inferior long-term outcomes compared ductal (IDC). In this study, we sought gain mechanistic insights into these clinical findings that not explained by genetic landscape identify strategies improve patient outcomes. comprehensive analysis epigenome in preclinical models samples showed that, IDC, harbored a...
<title>Abstract</title> High-Grade T1 (HGT1) Non-Muscle Invasive is an early-stage of Bladder Cancer (NMIBC) with unpredictable relapse and recurrence rate. New biomarkers are needed for patient risk prediction to determine treatment. Here, we analyze the molecular characteristics HGT1 NMIBC by combining multi-omics at bulk single-cell resolution. We have identified two chromatin states that reflect variable degrees basal luminal inflammatory characteristics. These subtypes show relevant...
<div>Abstract<p>Most invasive lobular breast cancers (ILC) are of the luminal A subtype and strongly hormone receptor–positive. Yet, ILC is relatively resistant to tamoxifen associated with inferior long-term outcomes compared ductal (IDC). In this study, we sought gain mechanistic insights into these clinical findings that not explained by genetic landscape identify strategies improve patient outcomes. comprehensive analysis epigenome in preclinical models samples showed that,...
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Data from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Data from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Data from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Data from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer